The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines

(2021) Alireza Mardanshahi et al.   MOLECULAR BIOLOGY REPORTS

Sirt4: A Multifaceted Enzyme at the Crossroads of Mitochondrial Metabolism and Cancer

(2020) Daniela Tomaselli et al.   Frontiers in Oncology

Oxidative Stress in Cancer

(2020) John D. Hayes et al.   CANCER CELL

Glutamic-Pyruvic Transaminase 1 Facilitates Alternative Fuels for Hepatocellular Carcinoma Growth—A Small Molecule Inhibitor, Berberine

(2020) Wei Guo et al.   Cancers

5-fluorouracil enhances the anti-tumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers

(2020) Yiqing Zhao et al.   CANCER RESEARCH

Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck

(2020) D. Day et al.   ORAL ONCOLOGY

Abrogating GPT2 in triple‐negative breast cancer inhibits tumor growth and promotes autophagy

(2020) Devina Mitra et al.   INTERNATIONAL JOURNAL OF CANCER

Mammalian Target of Rapamycin 2 (MTOR2) and C-MYC Modulate Glucosamine-6-Phosphate Synthesis in Glioblastoma (GBM) Cells Through Glutamine: Fructose-6-Phosphate Aminotransferase 1 (GFAT1)

(2019) Bo Liu et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome

(2019) Suzy Scholl et al.   EBioMedicine

Glutamine Synthetase Promotes Radiation Resistance via Facilitating Nucleotide Metabolism and Subsequent DNA Damage Repair

(2019) Shujun Fu et al.   Cell Reports

Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial

(2019) Samantha Cabral S. da Costa et al.   JOURNAL OF CLINICAL ONCOLOGY

Targets for improving tumor response to radiotherapy

(2019) Keywan Mortezaee et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

A Phase Ib Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity-Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma

(2019) Lara A. Dunn et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Targeting of β-catenin reverses radioresistance of cervical cancer with the PIK3CA E545K mutation

(2019) Wei Jiang et al.   MOLECULAR CANCER THERAPEUTICS

The Role of Sirtuins in Antioxidant and Redox Signaling

(2018) Chandra K. Singh et al.   ANTIOXIDANTS & REDOX SIGNALING

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

(2018) Dejan Juric et al.   JOURNAL OF CLINICAL ONCOLOGY

Leucine Signals to mTORC1 via Its Metabolite Acetyl-Coenzyme A

(2018) Sung Min Son et al.   Cell Metabolism

Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer

(2018) Hyun Ju Kim et al.   GYNECOLOGIC ONCOLOGY

The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer

(2018) Wei Jiang et al.   Journal of Hematology & Oncology

HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma

(2017) Wenzhu Li et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I

(2016) Andréia Cristina de Melo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer

(2016) Yujun Hao et al.   Nature Communications

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer

(2015) E. Deutsch et al.   ANNALS OF ONCOLOGY

Characterization of the Novel and Specific PI3K  Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

(2014) C. Fritsch et al.   MOLECULAR CANCER THERAPEUTICS

Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation

(2013) Lisha Xiang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

SIRT4 Has Tumor-Suppressive Activity and Regulates the Cellular Metabolic Response to DNA Damage by Inhibiting Mitochondrial Glutamine Metabolism

(2013) Seung Min Jeong et al.   CANCER CELL

The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4

(2013) Alfred Csibi et al.   CELL

The Hallmarks of Cancer and the Radiation Oncologist: Updating the 5Rs of Radiobiology

(2013) J.S. Good et al.   CLINICAL ONCOLOGY

ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation

(2012) Guoliang Qing et al.   CANCER CELL

Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming

(2012) Yoichiro Mitsuishi et al.   CANCER CELL

The Proteasome Activator PA200 Regulates Tumor Cell Responsiveness to Glutamine and Resistance to Ionizing Radiation

(2012) J. Blickwedehl et al.   MOLECULAR CANCER RESEARCH

Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity

(2010) F. Weinberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Detection of the mitochondrial and catalytically active alanine aminotransferase in human tissues and plasma

(2009) Glinghammar   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism

(2009) Ping Gao et al.   NATURE

p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc

(2008) N Sankar et al.   ONCOGENE

Is Akt the “Warburg kinase”?—Akt-energy metabolism interactions and oncogenesis

(2008) R. Brooks Robey et al.   SEMINARS IN CANCER BIOLOGY